Peptide safety: what to know before starting

Peptide therapies have surged in popularity as more people explore weight management, recovery, immune support, and anti-aging. But with that popularity comes a complicated mix of FDA-approved medications, compounded formulations, and unregulated research products. Understanding the differences, and the risks, is important before starting any peptide regimen.

FDA-approved vs. research vs. compounded peptides

Note: A peptide being "natural" or "bioidentical" does not mean it is safe or effective. BPC-157 has promising animal research but has never completed a human clinical trial. That does not make it dangerous; it means the evidence is incomplete.

Compounding pharmacies: 503A vs. 503B

503A pharmacies are traditional compounding pharmacies regulated by state pharmacy boards. They prepare medications based on individual prescriptions. 503B outsourcing facilities were created by the Drug Quality and Security Act of 2013 and register with the FDA, are subject to FDA inspections, and must follow cGMP standards. Generally, 503B facilities offer higher quality assurance.

• Look for PCAB accreditation (Pharmacy Compounding Accreditation Board)
• Ask for certificates of analysis (COAs) for potency and sterility
• Verify state licensure in good standing
• Confirm experience compounding sterile injectable medications
• Check for clear labeling with beyond-use dates and lot numbers

Recent FDA actions on compounded GLP-1s

Under federal law, pharmacies can compound copies of FDA-approved drugs when those drugs are on the FDA's shortage list. Both semaglutide and tirzepatide experienced genuine shortages beginning in 2022-2023. During that period, compounding pharmacies legally produced their own versions at lower cost.

In October 2024, the FDA removed tirzepatide from the shortage list, and in February 2025, it removed semaglutide. These decisions triggered legal challenges from compounding pharmacies and patient advocacy groups. Several federal courts issued temporary restraining orders allowing some compounders to continue production while litigation proceeded.

Note: The regulatory status of compounded GLP-1 agonists is changing rapidly. If you are currently using a compounded version, talk to your prescriber about your options. Do not abruptly stop a GLP-1 medication without medical guidance.

How to evaluate peptide quality

A certificate of analysis (COA) is a document from an independent laboratory that verifies a product's identity, purity, potency, and sterility. Reputable suppliers will provide COAs proactively or on request.

• Products sold without a prescription for injectables that require one
• Claims that a peptide can cure cancer, reverse aging, or produce results that sound too good to be true
• No COA available, or a COA that cannot be traced to a real laboratory
• Unusually low prices compared to established compounding pharmacies
• Sellers who ship internationally from countries with minimal pharmaceutical regulation
• Products labeled "for research use only" with dosing instructions for human use

Common side effects by peptide category

GLP-1 receptor agonists

Nausea, vomiting, diarrhea, and constipation are the most common side effects, typically worst during dose escalation and often improving over time. Rare but serious risks include pancreatitis and gallbladder disease.

Growth hormone secretagogues

Water retention, joint pain, tingling or numbness, increased hunger, and headaches. Patients with active cancer should avoid these due to theoretical tumor-growth concerns.

Healing peptides (BPC-157, TB-500)

Limited human safety data. Anecdotally reported: nausea, dizziness, headache, and injection site discomfort. BPC-157 may influence blood pressure and angiogenesis.

Drug interactions and contraindications

• GLP-1 agonists slow gastric emptying, which may affect absorption of oral medications including contraceptives and antibiotics
• GLP-1 agonists combined with insulin or sulfonylureas increase hypoglycemia risk
• Growth hormone secretagogues may affect blood glucose and insulin sensitivity
• Peptides promoting angiogenesis (like BPC-157) should be avoided in patients with active cancers
• Immunomodulatory peptides may interact with immunosuppressive medications
• Pregnancy and breastfeeding are contraindications for virtually all peptide therapies

Questions to ask your provider

• What is the evidence base for this peptide for my specific goal? Is it FDA-approved or based primarily on animal research?
• Where will my peptide be sourced? Is it from a licensed compounding pharmacy with certificates of analysis?
• What baseline labs should I have, and how often will we monitor bloodwork?
• What side effects should prompt me to stop and contact you?
• Are there interactions with my current medications?
• What is the expected timeline for results, and how will we evaluate whether it's working?
• What happens when I stop? Are there withdrawal effects or rebound issues?

Note: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy.

Sources

1. FDA Drug Shortages Database: Semaglutide and Tirzepatide Listings. accessdata.fda.gov.
2. Drug Quality and Security Act (DQSA): Section 503A and 503B Overview. fda.gov.
3. FDA Warning Letters to Compounders of GLP-1 Receptor Agonist Products (2024-2025). fda.gov.
4. Semaglutide Prescribing Information (Ozempic / Wegovy). Novo Nordisk.
5. Pharmacy Compounding Accreditation Board (PCAB) Standards. achc.org.
6. Tutunchi H, et al. Thymalin and Thymosin Alpha-1: clinical applications and safety profile. International Immunopharmacology. 2020;85:106698.
7. Sikiric P, et al. BPC-157: a review of its regenerative and protective properties. Current Pharmaceutical Design. 2018;24(18):2041-2047.